X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will support the advancement of OrsoBio’s obesity-focused portfolio, including TLC-3595, a potent, selective, small molecule, allosteric inhibitor of acetyl-CoA carboxylase 2 (ACC2).
Lead Product(s): TLC-3595
Therapeutic Area: Endocrinology Product Name: TLC-3595
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Longitude Capital
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 07, 2023
Details:
TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and NASH.
Lead Product(s): TLC-6740
Therapeutic Area: Nutrition and Weight Loss Product Name: TLC-6740
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
TLC-3595 is a novel and selective ACC2 inhibitor designed to treat type 2 diabetes by increasing FAO, reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver
Lead Product(s): TLC-3595
Therapeutic Area: Endocrinology Product Name: TLC-3595
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
OrsoBio has recently acquired novel compounds and intellectual property for four programs, including inhibitors of acetyl-CoA carboxylase-2 (TLC-3595), liver X receptor, and aminocarboxymuconate semialdehyde decarboxylase, as well as a portfolio of mitochondrial protonophores.
Lead Product(s): TLC-3595
Therapeutic Area: Endocrinology Product Name: TLC-3595
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
ACMSD is a key enzyme involved in the de novo synthesis of NAD+, which is critical to mitochondrial function via maintenance of cellular redox state. TLC-065, is being advanced for the treatment of a range of metabolic and inflammatory liver and kidney disorders.
Lead Product(s): TLC-065
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TLC-065
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Mitobridge
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 02, 2022
Details:
TLC-3595 (formerly S-723595), a novel and selective ACC2 inhibitor, is designed to treat type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver.
Lead Product(s): TLC-3595
Therapeutic Area: Endocrinology Product Name: TLC-3595
Highest Development Status: Phase IProduct Type: Undisclosed
Recipient: Shionogi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 02, 2022
Details:
TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal lipid absorption.
Lead Product(s): TLC-2716
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Phenex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 02, 2022
Details:
TLC-1235, a novel, controlled-release mitochondrial protonophore, increases energy expenditure and is expected to have broad, systemic metabolic and cardiovascular benefits, including improved insulin sensitivity, NASH, dyslipidemia, and weight loss.
Lead Product(s): TLC-1235
Therapeutic Area: Dermatology Product Name: TLC-1235
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Yale University
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 02, 2022
Details:
TLC-6740 is a novel, liver-targeted mitochondrial protonophore in development for the treatment of severe lipodystrophies and other metabolic disorders. Based on active hepatic uptake and mitochondrial protonophoric activity.
Lead Product(s): TLC-6740
Therapeutic Area: Dermatology Product Name: TLC-6740
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Samsara BioCapital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
TLC-2716 is a liver-targeted inverse agonist of the Liver X Receptor (LXR) for the treatment of severe hypertriglyceridemia, familial hypercholesterolemia and NASH.
Lead Product(s): TLC-2716
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
